Lp(a) lipoprotein in cardiovascular disease

This 1994 review is, in effect, a time capsule — a synthesis of the first two decades of knowledge about lipoprotein(a), written before the tools existed to prove what it suspected.

Its enduring contributions are the observations that have since held up: that Lp(a) levels are overwhelmingly set by genetics and resist lifestyle change, that the population distribution is strangely skewed, that few things move an inherited level (endocrine shifts and hormones among them), and that Lp(a) tracks strongly and independently with atherosclerotic disease. The author even noted that sex hormones may shield premenopausal women — foreshadowing the rise in Lp(a) seen after menopause.

Where it overreached is instructive too: a proposed autoimmune/HLA mechanism never panned out, and the review predates both the Mendelian-randomization studies that later established causality and the oxidized-phospholipid biology that explained the inflammation.

We rate the evidence moderate. As a narrative review built on the observational evidence of its day, it lacked the causal tools and assay standardization that came later — but its core claims about genetic determination, distribution, and cardiovascular risk were vindicated. Its clinical significance is similarly moderate and largely historical: it helped establish Lp(a) as a serious, genetically fixed risk factor worth attention, setting up the targeted therapies that wouldn’t arrive for another thirty years. Read it as the field’s foundation, not its current state.